of Neuroscientific Knowledge to Social Aims
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)
Opioid Dependence
November 19-21, 2021
Heroin Addiction &
Related Clinical Problems
European Opioid Addiction Treatment Association - EUROPAD
14
14 th th European Congress European Congress
World Trade Center Grenoble 5-7, place Robert Schuman - BP 1521
38025 GRENOBLE CEDEX 1 Phone +33 476 28 28 82
www.congres-wtcgrenoble.com www.congres-wtcgrenoble.com
University of Grenoble GRENOBLE
FRANCE-EU
Hybrid Congress
Hybrid Congress
AU CNS
Association for the Application of Neuroscientific Knowledge
to Social Aims
Europod I
European Opioid Addiction Treatment Association
Per aspera ad astra Since 1994
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE
Scientific Committee of Grenoble2021Europad Coordinators
Icro Maremmani (Pisa, Italy) Maurice Dematteis (Grenoble, France) Marc Reisinger (Brussels, Belgium) Andrej Kastelic (Ljubljana, Slovenia)
Local Scientific Committee
Michel Mallaret (Grenoble, France) Lucie Pennel (Grenoble, France) Georges Brousse (Clermont-Ferrand)
International Scientific Committee
Adrian-Octavian Abagiu (Bucarest, Romania) Mercedes Lovrecic (Ljubljana, Slovenia) Hannu Alho (Helsinki, Finland) Angelo G. I. Maremmani (Viareggio, Italy) Marc Auriacombe (Bordeaux, France) Garrett McGovern (Dublin, Ireland) Alexander Baldacchino (St Andrews, Scotland, UK) Haim Mell (Jerusalem, Israel) Barbara Broers (Geneve, Switzerland) Mario Miccoli (Pisa, Italy) Miguel Casas (Barcelona, Spain) Genci Mucullari (Tirana, Albania)
Thomas Clausen (Oslo, Norway) Lubomir Okruhlica (Bratislava, Slovak Republic) Michael Farrell (Sydney, New South Wales, Australia) Mark Parrino (Ney York, New York, USA) Loretta Finnegan (Satellite Beach, Florida, USA) Matteo Pacini (Pisa, Italy)
Gabriele Fischer (Vienna, Austria) Luis Patricio (Lisbon, Portugal) Carla Gambarana (Siena, Italy) Einat Peles (Tel Aviv, Israel) Gilberto Gerra (Parma, Italy) Giulio Perugi (Pisa, Italy)
Edward Jacek Gorzelanczyk (Bydgoszcz, Poland) Jens Reimer (Hamburg, Germany)
Milazim Gjocjaj (Pristina, Kosovo) Roncero Alonso Carlos (Salamanca, Spain) Liljana Ignjatova (Skopje, Macedonia) Lorenzo Somaini (Biella, Italy)
Alexander Kantchelov (Sofia, Bulgaria) Marta Torrens (Barcelona, Spain) Evgeny Krupitsky (St. Petersburg, Russia) Didier Touzeau (Paris, France)
Albrecht Ulmer (Stuttgart, Germany)
EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.
The vision
EUROPAD exists to improve the lives of non-medical users and their families and to reduce the
impact of illicit drug use on society as a whole. The Association works to develop opioid addiction
treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes
to, addiction treatment worldwide.
Organizing Committee
Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Under the Patronage of
World Federation for the Treatment of Opioid Dependence, New York, NY, USA
NGO with Special Consultative Status with United Nations Economic and Social Counsil (ECOSOC)
University of Grenoble, Grenoble, France, EU Fédération Française d’Addictologie
Mission interministérielle de lutte contre les drogues et les conduites addictives
Féderation Addiction
Promoted by
European Opioid Addiction Treatment Association, Pisa, Italy, EU
Association for the Application of Neuroscientific Knowledge to Social Aims,
Pietrasanta, Italy, EU
Pisa School of Experimental and Clinical Psychiatry, Pisa, Italy, EU
Registration for the conference.
Participation in the congress has a cost of € 200 and is limited to 100 participants according to all anti-COVID measures. To register, you must use the website www.europad.org.
WEBINAR AND ASYNCHRONOUS ON-DEMAND MODE Registration for the webinar.
Participation in the webinar has a cost of € 100.
To register, you must use the website www.europad.org.
Subscribers will be sent an email from the organizing committee with instructions to connect to the webinar.
Asynchronous enrollment.
It is possible to participate in the symposia of the congress in asynchronous mode. The symposia originally planned in parallel will be accessible online from one week before the event up to one year after. Participation costs € 100. To register, you must contact the organizing secretariat
Provider CME EACCME
AU CNS
Association for the Application of Neuroscientific Knowledge
to Social Aims
Europod I
European Opioid Addiction Treatment Association
Per aspera ad astra Since 1994
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)
World Federation for the Treatment of
Opioid Dependence
PROGRAM
FRIDAY NOVEMBER 19, 2021
TIME ABSTRACTNo
⃝
⃝ ORAL PRESENTATIONS
On demand Europad Oral PresentationsChair: Angelo G. I. Maremmani (Viareggio, Italy, EU)
OP-1 MARC AURIACOMBE (Bordeaux, France, EU) - Substance Use Disorder Diagnosis and Craving: Comparison of Substance Users Accessing Treatment and Substance Users in Harm Reduction Programs.
0P-2 ROSHAN BHAD (New Delhi, India) - A Study of Pathways to Care, Stigma and Clinical Correlates of Treatment Seeking Natural Opioid Users in India: Implications for Opioid Crisis Management
0P-3 PETER ESPENSHADE (Montpellier, USA) - Neither Necessary nor Sufficient, the Role of Peers in the Recovery Workforce
OP-4 ZOZAN GULEKEN (Istanbul, Turkey) - Spectroscopy and Computer Based Analyse May Be a Tool for Early Diagnose of Inflammation for Opioid Use Disorder Patients
OP-5 ZUZANA KAMENDY (Bratislava, Slovakia) - Burnout Syndrome in Health Care Professionals in Addiction Treatment
OP-6 SORAYA MAYET (Hull, UK) - Tele-medicine in Addictions Randomised Controlled Trial
OP-7 LUCIE PENNEL (Saint-Martin d’Hères, France, EU) - Buprenorphine as a Last Resort Medication for Severe and Treatment Resistant Alcohol-Use Disorder: An Observational Compassionate Study
OP-8 Perrine ROUX (Marseille, France, eu) - Individualized Medicine in Harm Reduction : A Step Forward in the Treatment of Addiction
OP-9 SATARIYA TRAKULSRICHAI (Rajthevi, Thailand) - Kratom: Emerging Recreational Substance or Possible Medicinal Use?
OP-10 ALBRECHT ULMER (Stuttgart, Germany, EU) - Dihydrocodeine Vs. Acamprosate for the Medical Adjustment of Alcohol Dependent Patients
OP-11 SARAH VECCHIO (Biella, Italy, EU) - Assessment of potential benefits of injectable prolonged release buprenorphine formulations in an Italian Addiction Treatment Centre
⃝ EUROPAD PRE-CONGRESS SYMPOSIUM
On demand INTERNET PROBLEMATIC USE IS ASSOCIATED WITH PSYCHOPATHOLOGY SPECIFIC OF SUBSTANCE USE DISORDER
Chair: Liljana Ignjatova (Skopje, North Macedonia)
SE1-1 LILJANA IGNJATOVA (Skopje, North Macedonia) - Problematic Internet Use Among Youngsters
SE1-2 CATERINA FLORA (Paphos, Cyprus, EU) - European Network For Problematic Internet Use: Citizens Involvement. A Pilot Study In Parents, In Greece
SE1-3 FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Internet Problematic Use Is Associated with Psychopathology Specific of Substance Use Disorder
12:00-
12:30 Plenary
Webinar
ON LINE DISCUSSION OF ORAL PRESENTATIONS AND
SYMPOSIUM
FRIDAY NOVEMBER 19, 2021
TIME ABSTRACTNo 12:30-
14:00
Plenary In presence
Webinar
SHIFTING PARADIGMS: CLINICAL EXPERIENCE OF LONG-ACTING FORMULATIONS - Scientific session funded by industryScientific session funded by industry
Chair: Icro Maremmani (Pisa, Italy, EU)
SE4-1 ICRO MAREMMANI (Pisa, Italy, EU) - Is the Agonist Opioid Treatment Long Enough?
The Role of Long-acting Medications
SE4-2 LORENZO SOMAINI (Biella, Italy, EU) - Understanding long-acting formulations
SE4-3 CRAIG SAYERS (Larbert, UK) - Experience of using long-acting formulations in Scottish prisons
SE4-4 FADI MEROUEH (Montpellier, France EU) - Experience of using long-acting formulations in prisons in France
14:00-
15:30 Plenary Webinar
A BALANCING ACT: EFFECTIVE MANAGEMENT OF OPIOID USE DISORDER TO A BALANCING ACT: EFFECTIVE MANAGEMENT OF OPIOID USE DISORDER TO SUPPORT PATIENTS AND WIDER SOCIETY
SUPPORT PATIENTS AND WIDER SOCIETY − funded by industry − funded by industry Chair: Georges Brousse (Clermont-Ferrand, France, EU)
SE5-1 GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Introduction
SE5-2 HEINO STOVER (Frankfurt, Germany, EU) - Ongoing treatment challenges in the field of Opioid Use Disorder
SE5-3 STEPHAN WALCHER (Munich, Germany, EU) - What is Suboxone® film and what are the data that supports its use?
ALL FACULTY - Q&A and meeting close 15:30-
16:15
Plenary In presence
Webinar
EUROPAD SPECIAL EVENT funded by industry
Chair: Icro Maremmani (Pisa, Italy, EU)
SE3-1 LEVO-METHADONE IN ITALYLEVO-METHADONE IN ITALY
MARCO RIGLIETTA (Bergamo, Italy, EU) - LEVOPROACT: post-marketing surveillance in Italy
FRONTIERS IN ADDICTION MEDICINE Chair: Icro Maremmani (Pisa, Italy, EU) 16:15-
17:00
Plenary In presence
Webinar
MARC REISINGER (Brussels, Belgium, EU) - Climate Anxiety and Addictive Behaviours
FRIDAY NOVEMBER 19, 2021
ABSTRACT
TIME
⃝ PLENARY SESSION 1
Chair: Icro Maremmani (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)
17:00- 17:30
Plenary In presence
Webinar
ICRO MAREMMANI (Pisa, Italy, EU) & MAURICE DEMATTEIS (Grenoble, France) - Conference Opening
17:30- 18:00
PL-1 Plenary Webinar
MARK Parrino (New York, NY, USA) - Evolving Policy Issues with Opioid Use Disorder in the United States
18:00- 19:00
PL-2 Plenary In presence
Webinar
Sir JOHN STRANG (London UK) - Treatment of Opioid Use Disorder: Three Lessons to Learn from the Past and Changes We Must Make for a Better Future
19:00- 20:00
PL-3 Plenary In presence
Webinar
MAURICE DEMATTEIS (Grenoble, France, EU) - From Categories to Dimensions in Addiction Medicine and Mental Health: A Pragmatic Approach to Treat Patients from Harm Reduction to Recovery
20:00 BREAK
⃝
Welcome cocktailand eURoPad chimeRa aWaRd 2020- the alessandRo tagliamonte aWaRd Chairs: Icro Maremmani (Pisa, Italy, EU) - Marc Reisinger (Brussels, Belgium, EU)Andrej Kastelic (Ljubljana, Slovenia, EU)
20:30
PlenaryDEDICATED TO ROBERT NEWMAN, MARY JEANNE KREEK &
MICHEL REYNAUD
In presence To be awarded: STEPHAN WALCHER (Munich, Germany) Webinar GENCI MUCOLLARI (Tirana, Albania) In presence ANGELO G.I. MAREMMANI (Viareggio, Italy)
Career Award: HERMAN JOSEPH (New York, NY, USA) - To memory
Plenary In presence
Webinar
Plenary In presence
Webinar
Best poster Rovai Scholars award
SATURDAY NOVEMBER 20, 2021
TIME ABSTRACTNo 8:30-
10:00 Plenary
Webinar
SYMPOSIUM
⃝
1 - PAIN PSYCHIATRIC DISORDERS AND ADDICTIVE DISORDERS: GROWING EPIDEMIOLOGY AND COMMON PATHOPHYSIOLOGY PLEAD FOR INTEGRATED APPROACHESChair: Rolland Benjamin (Bron, France, EU)
S01-1 GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Type of Pain (Dolorosa) Matters: Physical or Mental, but the Human Partition Remains the Same
S01-2 MAURICE DEMATTEIS (Grenoble, France, EU) - Addictive, Psychiatric and Pain Disorders: Different Clinical Expressions but Final Common Pathways
S01-3 ARUN BHASKAR (London, UK) - Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder: Consensus and Controversies between European Pain and Addiction Specialists
On demand 2 - POTENTIAL ADVANCES IN METHADONE-BASED TREATMENT FOR OPIOID USE DISORDER
Chair: Sergi Ferré (Baltimore, MD, USA)
S02-1 SERGI FERRÉ (Baltimore, MD, USA) - Opioid-Galanin Receptor Heteromers Determine Weaker Dopaminergic Effects of Methadone as Compared to Morphine and Fentanyl
S02-2 ANNABELLE BELCHER (Baltimore, Ml, USA) - Harnessing Placebo Effects to Augment Methadone Treatment Retention
S02-3 DECLAN T. BARRY (New Haven, CT, USA) - Scale Up of Methadone Maintenance Treatment Using an Open-Access Model
⃝
3 - DIFFERENT CLINICAL APPROACHES TO REACH PERSONS WITH OPIOID USE DISORDER; HOW TO BEST ADAPT TO CHANGING PATIENTS’ NEEDSChair: Thomas Clausen (Oslo, Norway) - Gabriele Fischer (Vienna, Austria, EU)
S03-1 MARC AURIACOMBE (Bordeaux, France, EU) - The France Experience with Primary Care Level Provision of Buprenorphine for OUD as the Main Approach
SO3-2 GABRIELE FISCHER (Vienna, Austria, EU) - Slow Release Oral Morphine (SROM) as the Preferred Treatment for OUD: The Austrian Experience
S03-3 LARS TANUN (Oslo, Norway) - Long-Acting Injectable Partial Agonist and Antagonists: Promises and Pitfalls of Long-Acting Injectable for OUD
S03-4 THOMAS CLAUSEN (Oslo, Norway) - A Range of Clinical Approaches to Reach Persons with Opioid Use Disorder Within One Clinic
⃝
4 - VULNERABILITY TO ADDICTION Chair: David Belin (Cambridge, UK)S04-1 ALEJANDRO HIGUERA-MATAS (Valencia, Spain, EU) - Opioid Self-Administration Alters Brain Neurochemistry and Neural Plasticity Mediators: Modulation Following Withdrawal or Extinction.
S04-2 LUCIA HIPOLITO (Madrid, Spain, EU) - Inflammatory Pain Induces Dysregulation of the KORS and MORS within Mesocorticolimbic System: Impact on Heroin and Alcohol Self-Administration
S04-3 BENJAMIN BOUTREL (Prilly, Switzerland) - The Olievenstein’s broken mirror theory revisited: earlier life matters, how and why
S04-4 DAVID BELIN (Cambridge, UK) - Behavioural and Neural Basis of the Individual Vulnerability to Develop Compulsive Heroin Seeking Habits
10:00-
10:30 Plenary
Webinar ON LINE DISCUSSION ABOUT SYMPOSIA
TIME ABSTRACTNo
SATURDAY NOVEMBER 20, 2021
⃝ PLENARY SESSION 2
Chair: Icro Maremmani (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)
10:30- 12:30
Plenary In presence
Webinar
Round Table - New perspectives of depot medications in Heroin Use Disorder
Chair: Icro Maremmani (Pisa, Italy)
PS4 MICHAEL FROST (Conshohocken, PA, USA) - FADI MEROUEH (Montpellier, France EU) - MAURICE DEMATTEIS (Grenoble, France,EU) - LORENZO SOMAINI (Biella, Italy, EU) -
⃝ EUROPAD LUNCH SPECIAL CONFERENCE funded by industry
Chair: Icro Maremmani (Pisa, Italy, EU) 12:30-
13:30
Plenary In presence
Webinar
Sir JOHN STRANG (London UK) (Conshohocken, PA, USA) - Buprenorphine implant: A new strategy for Opioid Use Disorder patients engagement
13:30-
14:30 Plenary
Webinar
PLENARY SESSION 2
Chair: Jean-Pierre Daulouede (Bayonne, France, EU)
PL-4 MICHAEL FINGERHOOD (Baltimore, PA, USA) - Substance Use Disorders in Later Life
⃝ SYMPOSIUM
14:30- 16:00
Plenary In presence
Webinar
6 - USE OF PSYCHIATRIC MEDICATIONS IN DUAL DISORDER HEROIN USE DISORDER PATIENTS (in collaboration with World Association on Dual Disorder - WADD) Chair: Nestor Szerman (Madrid, Spain, Eu)
S06-1 NESTOR SZERMAN (Madrid, Spain, EU) - Opioid System and Mental Disorder
S06-2 ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Mood Disorders) Patients
S06-3 ICRO MAREMMANI (Pisa, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Psychotic Disorder) Patients
16:00- 17:00
Plenary In presence
Webinar
PLENARY SESSION 3
Chair: - Jean Jacques Deglon (Geneve, Switzerland)
PL-5 YIFRAH KAMINER (Farmington, CT, USA) - Determining Youth Intentional Lethal Opioids Over Dose: The Case of Psychological Autopsy to Complement the Medical Examiner Report
17:00-
19:00 Plenary
Webinar
PLENARY SESSION 4
Chair: Amine Benyamina (Paris, France, EU)
PL-6 PIER PAOLO PANI (Cagliari, Italy, EU) - Unitary View of Psychopathology of Addiction. From Neurobiology to Clinical Perspective
PL-7 IVAN MONTOYA (Rockville, Maryland, USA) - Therapeutic Perspective of Opioid
Partial Agonists in Addiction Medicine and Psychiatric Disorders
20:00 SPEAKERs’ DINNER*
* Tickets are available for all delegates
TIME No
SUNDAY NOVEMBER 21, 2021
On demand
SYMPOSIA
⃝
7 - SEEA NET SYMPOSIUM: PATIENTS TAILORED PROGRAMS - REALITY OR WISH (in collaboration with the South Eastern European and Adriatic Addiction Treatment Network)Chair: Andrej Kastelic (Ljubljana, Slovenia, Eu)
S07-1 ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Between Patients Needs, Expectations, Guidelines, Regulations and Law
S07-2 MIRJANA DELIC (Ljubljana, Slovenia, EU) - Different Dimensions of Wellness as a Part of Drug Addiction Treatment
S07-3 NUSA SEGREC (Ljubljana, Slovenia, Eu) - Treat or Not to Treat - Is This a Question?
⃝
8 - SELECTED EUROPAD PRESENTATIONS Chair: Matteo Pacini (Pisa,Italy, EU)S08-1 MARC AURIACOMBE (Bordeaux, France, Eu) - Buprenorphine Dose, Craving and Opioid Use Severity in a Naturalistic Treatment Setting
S08-2 PAOLA ROSCA (Jerusalem, Israel) - Suboxone Film in Opioid Maintenance Treatment Centers: The Israeli Pilot Study Experience
S08-3 GABRIELLE KATRINE WELLE-STRAND (Oslo, Norway) - Somatic and Mental Health of Women in Opioid Maintenance Treatment (OMT) 10 Years after Their Child Was Born
⃝
9 - HARM REDUCTION AS A KEY PRINCIPLE FOR ACCESS TO CARE: INSIGHTS FROM THE SWISS-ROMANDY COLLEGE OF ADDICTION MEDICINEChair: Olivier Simon (Lausanne, France, EU)
S09-1 GERARD CALZADA (Geneve, Switzerland) - Prescription of Pharmaceutical Heroin Versus a Safe Place for Consumption
S09-2 OLIVIER SIMON (Lausanne, France) - Applying Risk and Harm Reduction to Gambling?
S09-3
On demand DANIELE ZULLINO (Geneve, Switzerland) - From Heroin to Medical and No-Medical Cannabis
⃝
10 - UNDERSTANDING THE CURRENT OPIOID CRISIS: GLOBAL CRISIS OF NO-MEDICAL USE OF OPIOIDSChair: Mercedes Lovrecic (Ljublijana, Slovenia, EU)
S10-1 MERCEDES LOVRECIC ( Ljubljana, Slovenia, EU) - Outbreak of ‘Novel Synthetic Opioids’: No-Medical Use of Opioids
S10-2 MICHAEL J. BANNON (Detroit, MI, USA) - Decision Tree Analysis Reveals Recent Trends, Bio-markers, and Potential Drug Interactions Associated With Opioid Abuse
S10-3 MAREN WRIGHT VOSS (Salt Lake City, UT, USA) - A Pain Education and Opioid Monitoring Program for a Community Setting: Creating Safety and Screening around Prescribed Opioids
8:30-
10:00 Plenary
Webinar
SYMPOSIUM
⃝
5 - THE EUROPEAN ADDICTOVIGILANCE NETWORK: ROLE IN THE OPIOID EPIDEMICS AND IN OPIOID USE DISORDER WITH COMORBIDITIES (PAIN AND DUAL DISORDER) Chair: Michel Mallaret (Grenoble, France, EU)S05-1 MICHEL MALLARET (Grenoble, France, EU) - The European Addictovigilance Network:
Functioning and Role in the Epidemics of Opioid Substances and Their Regulation
S05-2 JOELLE MICALLEF (Marseille, France, EU) - Opioid Addiction in No-Cancer Chronic Pain Patients: Results from the French Addictovigilance Network
S05-3 MARYSE LAPEYRE-MESTRE (Toulouse, France, EU) - Opioid Addiction in ADHD Patients: Results from the French Addictovigilance Network
10:00-
10:45 Plenary
Webinar ON LINE DISCUSSION ABOUT SYMPOSIA
SUNDAY NOVEMBER 21, 2021
Room
and time ABSTRACTNo
On demand
SYMPOSIA
⃝
11 - INTEGRATED PSYCHIATRIC REHABILITATION FOR PATIENTS WITH DUAL DISORDERS: TOWARDS SOCIAL AND PERSONAL RECOVERYChair: Julien Dubreucq (St Martin d’Hères, France, EU)
S11-1 JULIEN DUBREUCQ (St Martin d’Hères, France, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in France: The Experience from Grenoble
S11-2 YASSER KHAZAAL ( Lausanne, Switzerland, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in Switzerland: The Experience from Lausanne
S11-3 KIM MUESER (Boston, MA, USA) - Recovery-Oriented Treatment for Patients with Dual Disorders in the USA: The Experience from Boston
⃝
12- ADDICTION, INFECTIOUS DISEASES, ETHIC: HEALTHCARE IN PRISON Chair: Fadi Meroueh (Montpellier, France, EU)S12-1 FADI MEROUEH (Montpellier, France, EU) - Elimination of Hepatitis C in Prison:
Essential Combination Treatment with Harm Reduction
S12-2 ROBERT TELTZROW (Paris, France, EU) - New Psychoactive Substances in Prison – an Incalculable Risk for European Prisons?
S12-3 LINDA MONTANARI (Lisbon, Portugal, EU) - Drug Related Interventions in Europeans Prison: Evidence and Availability
⃝
13 - SUBSTANCE USE AND HUMAN RIGHTS Chair: Marta Torrens (Barcelona, Catalonia, Spain)S13-1
On demand PETER KASTNER (Vienna, Austria, Eu) - Monitoring Human Rights Under the National Prevention Mechanism (NPM) Including Nelson Mandela Rules
S13-2
On demand LINDA MONTANARI (Lisbon, Portugal, EU) - HCV in Europeans Prison in Persons with Drug Related Problems
S13-3
On demand GABRIELE FISCHER (Vienna, Austria) - Hepatitis C and Attention-Deficit Hyperactivity Disorder in a High-Risk Group of Opioid-Maintained Prisoners
⃝
14 - BENZODIAZEPINE USE AND ABUSE IN OPIOID AGONIST TREATMENT Chair: Martin Haraldsen (Sandefjord, Norway)S14-1 On demand
MARTIN HARALDSEN (Sandefjord, Norway) - Benzodiazepine Stabilisation Treatment (BST) in Conjunction with Opioid Agonist Treatment (OAT): The Experience from a Norwegian Town General Practice Supporting BST
S14-2
On demand ADAM BAKKER (London, Uk) - Benzodiazepine Maintenance in Opioid Agonist Treatment (OAT), Good or Bad?
S14-3
On demand FERGUS LAW (Bath, Uk) - Opioid Overdose and a New Model of Drug Use and Tolerance with Implications for Treatment
⃝
15 - METHADONE-ASSISTED PSYCHOTHERAPY (in collaboration with the Kantchelov Clinic)Chair: Alexander Kantchelov (Sofia, Bulgaria)
S15-1
On demand RICK BES (Hilversum, Netherlands, EU) - Facilitating Change: Implementation of Mi (Motivational Interviewing) in Methadone-Assisted Psychotherapy
S15-2
On demand TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - From Specific Psychopathology Towards Psychotherapeutic Strategies in Opioid Addiction Treatment
S15-3
On demand ROBERT LAMBERT (Waterbury, Connecticut, USA) - Increasing Retention in Comprehensive Methadone Treatment by Integrating a Patient Centred Approach 10:45-
11:45 Plenary
Webinar ON LINE DISCUSSION ABOUT SYMPOSIA
⃝ SUNDAY NOVEMBER 21, 2021
On demand POSTER SESSION
P-01 CHRISTER AAS (Bergen, Norway) - Quality of Life among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study
P-02 SEKER BURCU CETIN (Üsküdar, İstanbul Turkey) - Opioid Use of the Patients Who Have Both Addiction and a Risk of Ptsd in an Addiction Outpatient Counseling Center
P-03 LARS T. FADNES (Bergen, Norway) - Effect of Integrated Treatment of Hepatitis C among People with Opioid Addiction: Results from a Multicenter Randomised Controlled Trial
P-04 MOHAMED FARAH et al. (Massy, France, EU) - Risk-Adjusted Abstinence Rates Are Higher with Greater Buprenorphine Plasma Exposure among Patients Who Inject Opioids
P-05 DIMY FLUYAU (Tyrone, GA, USA) - N-Methyl-D-Aspartate Receptor Antagonists for Opioid Dependence
P-06 FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain) - A Multidisciplinary Approach to Treat Hepatitis C Infection in Heroin Addicted Patients
P-07 FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain, EU) - Reaching the 90- 90-90 Unaids Treatment Target for People Who Inject Drugs Receiving Integrated Clinical Care in a Drug Use Outpatient Treatment Facility
P-08 ALLISON GALLANT ( Saint John, Canada) - Prevalence and Trends of Illicit Drug Use and Retention in a Low Threshold/High Tolerance Methadone Maintenance Treatment Program
P-09 ZHANNA GAULEN et al. (Bergen, Norway) - Changes in Life Satisfaction among Opioid-Dependent Individuals Treated with Extended-Release Naltrexone or Buprenorphine-Naloxone
P-10 AARON GREENBLATT (Baltimore, MD, USA ) - Race-Based Differences in Self- Reported Drug Use at an Urban Methadone Treatment Program
P-11 HOLLY HILLS (Tampa, FL, USA) - Service Delivery to Persons with Opioid Use Disorders During the Pandemic: Examination of the Rapid Adaptation and Implementation of Practice Changes
P-12 MARGAUX KOSIM et al. (Paris, France, EU) - Patient Acceptance and Willingness to Use a New Formulation of Long Acting Buprenorphine- AMBRE Survey Results
P-13 JIMMY LANGLOIS et al. (Quebec, Canada) - Psychosocial outreach during outpatient low-barrier detoxification process with vulnerable people disaffiliated from formal health care system
P-14 AMANDA LIBERMAN et al.(New Haven, CT, USA) - Decisional considerations for methadone uptake In Kyrgyz prisons
P-15 MERCEDES LOVRECIC et al. (Ljubljana, Slovenia, EU) - The Filing of Addicted Patients at Addiction Units Is Correlated with a Reduction in Mortality Due to Illicit Opioids, but Also to Prescribed Opioids and Other Abused Substances
P-16 NERMANA MEHIĆ-BASARA et al. (Sarajevo, Bosnia and Herzegovina) - Somatic Complications in Homeless Heroin Addict in the AOT Program - Case Report
P-17 PASCAL MELIN et al. (Saint Dizier, France, EU ) - The Right Patient in the Right Way:
“Road trip Hépatant”
P-18 KALIA NIKOLAU (Limassol, Cyprus, EU) - The Role of Dynamic Inter-Family Characteristics in Drug Addiction
P-19 WALTER PAGANIN et al. (Tivoli (RM), Itally, EU) - Depression Resistant to Antidepressant Medications or Depression Complicated by Hypophoria? (a Case Report)
P-20 CRAIG SAYERS (Larbert, UK) - Evaluation of Covid-19 Contingency Planning in Scottish Prisons: Outcomes and Resource Utilisation Following Introduction of Injectable Prolonged-Release Buprenorphine (Prb)
P-21 GABRIEL SHAYA et al. (Slough, UK ) - Reducing Relapse with Buprenorphine:
Findings from the Costedopia & German Real-World Studies
P-22 MARIA GIOVANNA TOCCO et al. (Milan, Italy, EU) - High Therapeutic Buprenorphine Levels Reduce Iv Fentanyl Respiratory Depression
P-23 JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Towards a Common Metric for Assessing Heroin-Dependent Patient Satisfaction with Medications: Satisfaction with Methadone as a Gold Standard?
P-24 JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Quality of Life and Well- Being from the Perspective of Patients on Opioid Agonist Maintenance Treatment: A Synthesis of Qualitative Research
P-25 ALBRECHT ULMER (Stuttgart, Germany, EU) - Quintessence: What Have I Learned in the 30 Years of Treatment of Addicted Patients?
P-26 ALBRECHT ULMER (Stuttgart, Germany, EU) - The Nonsense and Crime of Prohibition
P-27 GABRIEL VALLECILLO et al. (Barcelona, Catalonia, Spain, EU) - Increased
Cardiovascular Risk among Older Adults with Heroin Use Disorder: A Comparative Study with the Population-Based REGICOR Cohort
P-28 JORN HENRIK VOLD (Bergen, Norway) - Mental Health Symptoms among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study 11:45-
12:45 Plenary
Webinar ON LINE DISCUSSION ABOUT POSTERSESSION 12:45-
12:00
Plenary In presence
Webinar
ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Pisa, Italy, in May 20-22, 2022!
Faculty
Christer AAS Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: christer.frode.aas@helse-bergen.no]
Marc AURIACOMBE University of Bordeaux, Bordeaux, France, EU - [E-Mail: marc.
auriacombe@u-bordeaux.fr]
Adam BAKKER Lisson Grove Health Centre, NHS, London, UK - [E-Mail: bakkerismo@gmail.
com]
Michael J. BANNON Wayne State University School of Medicine, Department of Pharmacology, Detroit, MI, USA - [E-Mail: mbannon@med.wayne.edu]
Declan T. BARRY Yale University School of Medicine, New Haven, CT, USA - [E-Mail: declan.
barry@yale.edu]
Annabelle BELCHER University of Maryland School of Medicine, Baltimore, ML, USA - [E-Mail:
abelcher@som.umaryland.edu]
David BELIN University of Cambridge, Department of Psychology, Cambridge, UK - [E-Mail: bdb26@cam.ac.uk]
Rick BES Centre for Motivation and Change, ,Hilversum, Netherlands, EU - [E-Mail:
rikbes@me.com]
Roshan BHAD All India Institute of Medical Sciences (AIIMS), New Delhi, India - [E-Mail:
drroshansindia@gmail.com]
Arun BHASKAR Imperial College London, UK [E-Mail: akbhaskar@btinternet.com]]
Benjamin BOUTREL Lab on the Neurobiology of Eating and Addictive Disorders, CHUV- Department of Psychiatry, Prilly, Switzerland - [E-Mail: benjamin.boutrel@
unil.ch]
Georges BROUSSE CHU Clermont-Ferrand University, Clermont-Ferrand, France, EU - [E-Mail:
gbrousse@chu-clermontferrand.fr]
Seker BURCU CETIN Turkish Green Crescent Society Counseling Center, Üsküdar, İstanbul Turkey - [E-Mail: burcu.cetin@yesilay.org.tr; burcucetin@windowslive.com]
Gerard CALZADA Service d'addictologie des HUG and College Romand de Médecine de l’Addiction, Geneve, Switzerland - [E-Mail: Gerard.Calzada@hcuge.ch]
Thomas CLAUSEN Oslo University Hospital, Oslo, Norway - [E-Mail: thomas.clausen@medisin.
uio.no]
Jean-Pierre DAULOUEDE Centre Hospitalier de la Côte Basque, Bayonne, France, EU - [E-Mail:
jeanpierredaulouede@gmail.com]
Mirjana DELIC Ljubljana, Slovenia, EU - [E-Mail: mirjana.delic@psih-klinika.si]
Jean Jacques DEGLON Geneve, Switzerland - [E-Mail: jjdeglon@gmail.com]
Filippo DELLA ROCCA School of Psychiatry, University of Pisa Pisa, Italy, EU - [E-Mail: filippo.
dellarocca@yahoo.it]
Maurice DEMATTEIS Grenoble Alpes University Hospital, Grenoble, France, EU, Grenoble, France, EU - [E-Mail: MDematteis@chu-grenoble.fr]
Julien DUBREUCQ Centre Référent de Réhabilitation Psychosociale et de Remédiation cognitive, St Martin d'Hères, France, EU - [E-Mail: julien.dubreucq@
hotmail.fr]
Peter ESPENSHADE Recovery Vermont, Montpelier, USA - [E-Mail: peter@recoveryvermont.
org]
Lars T. FADNES Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: Lars.Fadnes@uib.no]
Mohamed FARAH Indivior France, Massy, France, EU - [E-Mail: mohamed.farah@indivior.
com]
Sergi FERRÉ National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA - [E-Mail: sferre@intra.nida.nih.gov]
Michael FINGERHOOD Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Bayview Hospital Medical Center, Baltimora, Maryland, USA - [E-Mail: mifinger@
jhmi.edu]
Gabriele FISCHER Department for Psychiatry & Psychotherapy, Medical University Vienna, EU, Austria - [E-Mail: gabriele.fischer@meduniwien.ac.at]
Caterina FLORA Clinical Psychology, Paphos, Cyprus, EU, Paphos, Cyprus, EU - [E-Mail:
k.flora@nup.ac.c]
Dimy FLUYAU Emory University- School of Medicine, Tyrone, GA, USA - [E-Mail: dimy.
fluyau@emory.edu]
Francina FONSECA Institute of Neuropsychiatry and Addictions (INAD), Hospital del Mar Medical Research Institute-IMIM. Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Michael FROST Frost Medical Group, Conshohocken, PA, USA - [E-Mail: drfrost@verizon.
net]
Allison GALLANT Dalhousie University, Horizon Health Network, Saint John, Canada, Saint John, Canada - [E-Mail: allison.gallant@dal.ca]
Zhanna GAULEN Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. The University of Bergen, Bergen, Norway - [E-Mail: zhanna.
gaulen@helse-bergen.no]
Aaron GREENBLATT University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail:
agreenbl@som.umaryland.edu]
Zozan GULEKEN Üsküdar University , Istanbul, Turkey - [E-Mail: zozanguleken@gmail.com]
Martin HARALDSEN Sandefjord, Norway - [E-Mail: martinharaldsen@outlook.com]
Alejandro HIGUERA-MATAS Dpt. Farmàcia I Tec. Farmacèutica, Facultat Farmàcia, Universitat de València Valencia, Spain, EU - [E-Mail: ahiguera@psi.uned.es]
Lucia HIPOLITO Department of Psychobiology. School of Psychology. National University for Distance Learning (UNED), Madrid, Spain., EU - [E-Mail: lucia.hipolito@
uv.es]
Liljana IGNJATOVA University Psychiatric Clinic, Skopje, North Macedonia - [E-Mail: liljana.
kitevaignjatova@yahoo.com]
Zuzana KAMENDY Centre for Treatment of Drug Dependencies, Bratislava, Slovakia - [E-Mail:
zuzana.kamendy@gmail.com]
Yifrah KAMINER Alcohol Research Ctr at the University of Connecticut Medical School, Farmington, CT, USA - [E-Mail: Kaminer@psychiatry.uchc.edu]
Alexander KANTCHELOV The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@
gmail.com]
Andrej KASTELIC Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER Ombudsmen Instiute, Vienna, Austria, EU - [E-Mail: peter.kastner@
volksanwaltschaft.gv.at]
Yasser KHAZAAL Service de Médecine des Addictions, Lausanne, France, EU - [E-Mail: yasser.
khazaal@chuv.ch]
Margaux KOSIM Consultation Addictologie Pass Hopital Pitié Salpètriere, Paris, Ile De France, France, EU - [E-Mail: margaux.kosim@camurus.com]
Robert LAMBERT Connecticut Counseling Centers, Inc., Waterbury, Connecticut, USA - [E-Mail: rlambert@ctcounseling.org]
Jimmy LANGLOIS Université Laval, Québec, Canada - [E-Mail: jimmy.langlois.1@ulaval.ca]
Maryse LAPEYRE-MESTRE Addictovigilance, Toulouse, France, EU - [E-Mail: maryse.lapeyre-mestre@
univ-tlse3.fr]
Fergus LAW University of Bristol, Bath, UK - [E-Mail: fergus.law1@gmail.com]
Amanda LIBERMAN Yale University, New Haven, CT, USA
Mercedes LOVRECIC National Institute of Public Health, Ljubljana, Slovenia, EU, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Michel MALLARET Centre Addictovigilance CHU, Grenoble, France, EU - [E-Mail: mmallaret@
chu-grenoble.fr]
Angelo G. I. MAREMMANI Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Viareggio, Italy, EU - [E-Mail: angelogimaremmani@gmail.com]
Icro MAREMMANI Vincent P. Dole Dual Disorder Unit, 2nd Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmani@
med.unipi.it]
Soraya MAYET Humber Teaching NHS FT, Hull, UK, Hull, UK - [E-Mail: smayet@nhs.net]
Nermana MEHIĆ-BASARA Public Institute for Addiction Disorders of the Canton of Sarajevo, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina - [E-Mail: zalcnarc@
bih.net.ba]
Pascal MELIN CHG Saint Dizier, Saint Dizier, France, EU Saint Dizier, France, EU - [E-Mail:
pascalmelin@hotmail.fr]
Fadi MEROUEH Health Without Barriers, France, EU - [E-Mail: fadimeroueh@gmail.com]
Joelle MICALLEF Addictovigilance, , Marseille, France, EU - [E-Mail: joelle.micallef@ap-hm.fr]
Linda MONTANARI EMCDDA, Lisbon, Portugal, EU - [E-Mail: Linda.Montanari@emcdda.europa.
eu]
Ivan MONTOYA Division of Therapeutics and Medical Consequences (DTMC), NIDA, , Rockville, Maryland, USA - [E-Mail: imontoya@mail.nih.gov]
Kim MUESER Center for Psychiatric Rehabilitation,, Boston, MA, USA - [E-Mail: mueser@
bu.edu]
Kalia NIKOLAU University of Cyprus, Limassol, Cyprus, EU, Limassol, Cyprus, EU - [E-Mail:
kalianikolaou2@gmail.com]
Walter PAGANIN Department of Mental Health ASL RM/5, Tivoli (RM), Itally, EU - [E-Mail:
63walter@gmail.com]
Pier Paolo PANI Social-Health Services, Health District USL Cagliari, Italy, EU - [E-Mail:
pallolo@tin.it]
Mark PARRINO Americam Association for the Treatment of Opioid dependence, New York, New York, USA - [E-Mail: mark.parrino@aatod.org]
Lucie PENNEL Service Universitaire de Pharmaco-Addictologie-CSAPA, CHU Grenoble Alpes, Saint-Martin d'Hères, France, EU - [E-Mail: LPennel@chu-grenoble.
fr]
Marc REISINGER European Opioid Addiction Treatment Association, Brussels, Belgium, EU - [E-Mail: m.reisinger@proximus.be]
Marco RIGLIETTA Addiction Medicine Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy, EU - [E-Mail: mriglietta@asl.bergamo.it]
Benjamin ROLLAND Service Universitaire d’Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: Benjamin.ROLLAND@ch-le- vinatier.fr]
Paola ROSCA National Supervisor, Dept for the Treatment of Substance Abuse Ministry of Health, Jerusalem, Israel - [E-Mail: Paola.Roska@moh.gov.il]
Perrine ROUX Aix Marseille University, INSERM, IRD, SESSTIM, ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France, EU - [E-Mail: perrine.roux@inserm.fr.]
Craig SAYERS Prison Healthcare NHS Forth Valley, Larbert, UK - [E-Mail: craig.sayers@
nhs.scot]
Nusa SEGREC Center for treatment of drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: nusa.segrec@psih-klinika.si]
Gabriel SHAYA Indivior, Slough, UK - [E-Mail: naomi.dingwall@indivior.com]
Olivier SIMON Centre du Jeu Excessif, CHUV, Lausanne Et Collège Romand de Médecine de L'addiction, Lausanne, France - [E-Mail: Olivier.Simon@chuv.ch]
Lorenzo SOMAINI Drug Addiction Unit, Biella, Italy, EU - [E-Mail: Lorenzo.Somaini@aslbi.
piemonte.it]
Tsvetana STOYKOVA The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@
gmail.com]
Heino STOVER Frankfurt University of Applied Sciences, Frankfurt, Germani, EU - [E-mail:
hstoever@fb4.fh-frankfurt.de]
Sir John STRANG National Addiction Centre, Institute of Psychiatry, Psychology &
Neuroscience (IoPPN), King’s College London, London UK - [E-Mail: john.
strang@kcl.ac.uk]
Nestor SZERMAN Complutense University of Madrid, Spain, EU, Madrid, Spain, EU - [E-Mail:
nszermanb@gmail.com]
Lars TANUN Oslo University Hospital, , Oslo, Norway - [E-Mail: lars.tanum@ahus.no]
Robert TELTZROW Consultant Pompidou Group of the Council of Europe, Paris, France, EU - [E-Mail: Robert.TELTZROW@coe.int]
Maria Giovanna TOCCO Indivior Italia, Milan, Italy, EU - [E-Mail: giovanna.tocco@indivior.com]
Marta TORRENS Addiction Unit, Institute of Psychiatry and Addictions, Hospital del Mar- IMIM, University of Barcelona, Barcelona, Catalonia, Spain, EU - [E-Mail:
mtorrens@parcdesalutmar.cat]
Satariya TRAKULSRICHAI Ramathibodi Hospital, Rajthevi, Thailand - [E-Mail: satariya.tra@mahidol.
ac.th]
Joan TRUJOLS
Hospital de la Santa Cruz and Sant Pau / Sant Pau Biomedical Research Institute (IIB Sant Pau) / CIBER Mental Health (CIBERSAM), Barcelona, Catalonia, Spain,
EU - [E-Mail: jtrujols@santpau.cat]
Albrecht ULMER Institute for addiction research, Stuttgart, Germany, EU - [E-Mail: albrecht.
ulmer@gmx.de]
Gabriel VALLECILLO Institute of Neuropsychiatry and Addictions (INAD). Hospital del Mar Medical Research Institute-IMIM, Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: gvallecillo@parcdesalutmar.cat]
Jorn Henrik VOLD Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway, Bergen, Norway - [E-Mail: jorn.henrik.vold@helse-bergen.no]
Maren Wright VOSS Utah State University Extension, South Jordan, UT, USA, Salt Lake City, UT, USA - [E-Mail: maren.voss@usu.edu]
Stephan WALCHER CONCEPT, Munich, Germany, EU - [E-Mail: kontact@moviemed.de]
Gabrielle Katrine WELLE-
STRAND Norwegian Centre for Addiction Research (Seraf), University of Oslo, Oslo, Norway - [E-Mail: gabwel@online.no]
Daniele ZULLINO Service d'addictologie des hôpitaux universitaires de Genève et Collège romand de médecine de l'addiction, Geneve, Switzerland - [E-Mail: daniele.
zullino@hcuge.ch]
Miguel Casas (Spain) - 2012 Matteo Pacini (Italy) - 2018 Thomas Clausen (Norway) -2014 Pier Paolo Pani (Italy) - 2004 Pascal Courty (France) -2012 Luis Patricio (Portugal) -2010 Jean-Jacques Deglon (Switzerland) - 2004 Einat Peles (Israel) -2016 Maurice Dematteis (France) - 2018 Slavko Sakoman (Croatia) - 2010 Sergey Dvoryak (Ukraine) -2010 Lorenzo Somaini (Italy) - 2014 Gabriele Fischer (Austria) - 2008 Marta Torrens (Spain) - 2006 Gilberto Gerra (Italy) - 2006 Didier Touzeau (France) - 2008
Ante Ivancic (Croatia) - 2006 Ambros Uchtenhagen (Switzerland) - 2016 Alexander Kantchelov (Bulgaria) - 2004 Peter Vossenberg (The Netherlands) - 2016 Andrej Kastelic (Slovenia) - 2008 Helge Waal (Norway) - 2012
Mercedes Lovrecic (Slovenia) - 2002 Gabrielle Welle-Strand (Norway) - 2018
F
ormerc
areera
wardr
ecipients:
Jean-Pierre Daulouede (France) - 2016 Robert Newman (USA) - 2012 Loretta Finnegan (USA) - 2010 Marc Reisinger (Belgium) - 2004 Mary Jeanne Kreek (USA) - 2014 Mark Parrino (USA) - 2018
Joyce Lowinson (USA) - 2007 Alessandro Tagliamonte (Italy) - 2004 Icro Maremmani (Italy) - 2004
“The Luca Rovai Award”
“Dedicated to all those who dream of a better world for drug addicts”
PISA-School of Clinical and Experimental Psychiatry
ROVAI SCHOLARS AWARD ROVAI SCHOLARS AWARD
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)
AU-CNS
Association for the Application of Neuroscientific Knowledge to Social Aims Helping people to understand neuroscientific update
F
oRmeRR
eciPients:
From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Marem- mani. Poster presented at New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives” Pisa, Italy, October 22-23 2018
High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R.V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen. Poster presented at 2°
World Congress of the World Association on Dual Disorders (WADD), Florence, October 25-27 2018
Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tri- Rovai Scholars award, named after one of the founding member of PISA-School of Experimental and Clinical Psychiatry Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Ex- perimental and Clinical Psychiatry and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.
